findmyKOL
Clinical trialNCT05509855Enrolling, by, invitationObservational

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

SponsorWugen, Inc.Enrollment44T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Peter Maccullam Cancer Center

    Melbourne, Australia

United States
  • City of Hope

    Duarte, California, United States

  • Childrens Hospital la

    Los Angeles, California, United States

  • Washington University

    St Louis, Missouri, United States

  • Children'S Hospital of Philadelphia

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Aug 2022
Primary completion
1 Jul 2037
Completion
1 Jul 2037
Last update posted
20 Nov 2024
Registered enrollment
44
Registry id
NCT05509855

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.